Operational strategies in US cancer centers of excellence that support the successful accrual of racial and ethnic minorities in clinical trials.
Cancer research
Clinical trials
Disparities
Diversity and inclusion
Operations
Racial and ethnic minority groups
Journal
Contemporary clinical trials communications
ISSN: 2451-8654
Titre abrégé: Contemp Clin Trials Commun
Pays: Netherlands
ID NLM: 101671157
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
12
08
2019
revised:
09
01
2020
accepted:
19
01
2020
entrez:
15
2
2020
pubmed:
15
2
2020
medline:
15
2
2020
Statut:
epublish
Résumé
Study populations in clinical research must reflect US changing demographics, especially with the rise of precision medicine. However, racial and ethnic minority groups (REMGs) have low rates of participation in cancer clinical trials. Criteria were developed to identify cancer centers able to accrue a higher than average proportion of REMGs into clinical trials. Comprehensive interviews were conducted with leaders of these cancer centers to identify operational strategies contributing to enhanced accrual of REMGs. Eight US cancer centers reported a REMG accrual rate range in cancer research between 10 and 50% in a 12-month reporting period and met other criteria for inclusion. Fourteen leaders participated in this assessment. Key findings were that centers: had a metric collection and reporting approach; routinely captured race and ethnicity data within databases accessible to research staff; had operational standards to support access and inclusion; developed practices to facilitate sustained patient participation during clinical trials; had strategies to decrease recruitment time and optimize clinical study design; and identified low-resource strategies for REMG accrual. There was also a clear commitment to establish processes that support the patient's provider as the key influencer of patient recruitment into clinical trials. We have identified operational practices that facilitate increased inclusion of REMGs in cancer trials. In order to establish a sustainable cancer center inclusion research strategy, it is valuable to include an operational framework that is informed by leading US cancer centers of excellence.
Sections du résumé
BACKGROUND
BACKGROUND
Study populations in clinical research must reflect US changing demographics, especially with the rise of precision medicine. However, racial and ethnic minority groups (REMGs) have low rates of participation in cancer clinical trials.
METHODS
METHODS
Criteria were developed to identify cancer centers able to accrue a higher than average proportion of REMGs into clinical trials. Comprehensive interviews were conducted with leaders of these cancer centers to identify operational strategies contributing to enhanced accrual of REMGs.
RESULTS
RESULTS
Eight US cancer centers reported a REMG accrual rate range in cancer research between 10 and 50% in a 12-month reporting period and met other criteria for inclusion. Fourteen leaders participated in this assessment. Key findings were that centers: had a metric collection and reporting approach; routinely captured race and ethnicity data within databases accessible to research staff; had operational standards to support access and inclusion; developed practices to facilitate sustained patient participation during clinical trials; had strategies to decrease recruitment time and optimize clinical study design; and identified low-resource strategies for REMG accrual. There was also a clear commitment to establish processes that support the patient's provider as the key influencer of patient recruitment into clinical trials.
CONCLUSION
CONCLUSIONS
We have identified operational practices that facilitate increased inclusion of REMGs in cancer trials. In order to establish a sustainable cancer center inclusion research strategy, it is valuable to include an operational framework that is informed by leading US cancer centers of excellence.
Identifiants
pubmed: 32055746
doi: 10.1016/j.conctc.2020.100532
pii: S2451-8654(20)30016-8
pii: 100532
pmc: PMC7005557
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100532Subventions
Organisme : NCI NIH HHS
ID : UG1 CA233302
Pays : United States
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2020 The Author(s).
Références
J Oncol Pract. 2019 Apr;15(4):e289-e299
pubmed: 30830833
PLoS Med. 2015 Dec 15;12(12):e1001918
pubmed: 26671224
Front Oncol. 2011 Jun 22;1:11
pubmed: 22649752
J Natl Cancer Inst. 2015 Feb 09;107(4):
pubmed: 25667420
Asia Pac J Clin Oncol. 2018 Feb;14(1):52-60
pubmed: 29083094
CA Cancer J Clin. 2016 May;66(3):182-202
pubmed: 26766789
N Engl J Med. 2016 Nov 17;375(20):1998-2004
pubmed: 27635471
Cancer. 2008 Feb 1;112(3):447-54
pubmed: 18085590
NPJ Precis Oncol. 2017 Mar 20;1(1):2
pubmed: 29872692
J Oncol Pract. 2012 Mar;8(2):91-6
pubmed: 23077435
Oncologist. 2009 May;14(5):468-75
pubmed: 19401521
Nat Med. 2011 Mar;17(3):297-303
pubmed: 21383744
Cancer Control. 2008 Jul;15(3):260-8
pubmed: 18596679
Front Immunol. 2018 Mar 21;9:552
pubmed: 29619026